MAPT and Alzheimer disease: These P301L cases, characterized previously for tau pathology and confirmed to lack confounding proteinopathies [6, 54], were augmented by a number of controls including Alzheimer’s disease cases, frontotemporal dementia with progranulin mutations, amyotrophic lateral sclerosis cases, and non-demented controls.